In Q2 2025, Eventide Asset Management held 180 positions worth $4.4B. They initiated 21 new positions and exited 91. Their largest holding was VRNA ($256.8M). Portfolio value grew +17.2% versus the prior quarter.
Frequently asked questions
What stocks did Eventide Asset Management own in Q2 2025?
Eventide Asset Management held 180 biotech stocks in their 13F portfolio in Q2 2025. Their top positions include VRNA, GH, TT, MIRM, INSM. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Eventide Asset Management's portfolio worth in Q2 2025?
Eventide Asset Management's tracked biotech portfolio was worth $4.4B across 180 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Eventide Asset Management buy in Q2 2025?
Eventide Asset Management initiated 21 new positions in Q2 2025, including ORIC, TLN, SAPGF, TRVI, FITBM and 16 more. They also increased 108 existing positions.
What did Eventide Asset Management sell in Q2 2025?
Eventide Asset Management fully exited 91 positions in Q2 2025, including SPT, COUR, CWEN-A, BEPC, BILL and 86 more. They also trimmed 42 existing positions.
Is Eventide Asset Management a biotech fund?
Values-based investment firm with significant biotech allocation. Kuruvilla—a physician, engineer, and PhD—leads a team that evaluates companies on both financial merit and alignment with ethical principles. Known for holding high-conviction biotech positions alongside broader healthcare and technology investments.
Want AI analysis, insider signals, and catalyst overlays for Eventide Asset Management?
View latest Eventide Asset Management portfolio →